# The Role of suPAR Biomarker in Blood Samples of Breast Cancer Patients During and Post Doxorubicin Chemotherapy: Causative vs. Predictor

> **NCT03505164** · — · COMPLETED · sponsor: **Rush University Medical Center** · enrollment: 42 (actual)

## Conditions studied

- Doxorubicin Adverse Reaction
- Cardiomyopathies, Secondary
- Breast Cancer

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT03505164
- **Lead sponsor:** Rush University Medical Center
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2017-01-17
- **Primary completion:** 2020-07-06
- **Final completion:** 2020-07-06
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2021-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03505164

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03505164, "The Role of suPAR Biomarker in Blood Samples of Breast Cancer Patients During and Post Doxorubicin Chemotherapy: Causative vs. Predictor". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03505164. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*